Genentech reported yesterday that lampalizumab did not meet the primary endpoint in SPECTRI, one of the two parallel Phase III clinical trials investigating lampalizumab injections for the treatment of geographic…
In June, Novartis announced results from HAWK and HARRIER, two phase III clinical trials comparing brolocizumab (formerly RTH258) to aflibercept for the treatment of wet AMD. The primary endpoints were…
Day 4 of the ASRS annual meeting has provided us with even more clinically relevant information regarding neovascular age-related macular degeneration (nvAMD) and retinal detachments (RDs). Both Geoffrey Emerson and…
Genentech is again pursuing novel and creative ways to improve patient outcomes by testing long-term anti-VEGF delivery in the LADDER trial (Study of the Efficacy and Safety of the Ranibizumab…